CN103169807A - Application of Chinese and western combined medicine in pharmacy - Google Patents
Application of Chinese and western combined medicine in pharmacy Download PDFInfo
- Publication number
- CN103169807A CN103169807A CN2013101242179A CN201310124217A CN103169807A CN 103169807 A CN103169807 A CN 103169807A CN 2013101242179 A CN2013101242179 A CN 2013101242179A CN 201310124217 A CN201310124217 A CN 201310124217A CN 103169807 A CN103169807 A CN 103169807A
- Authority
- CN
- China
- Prior art keywords
- medicine
- chinese medicine
- western
- parts
- chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 93
- 229940079593 drug Drugs 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 208000003950 B-cell lymphoma Diseases 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 241001530126 Scrophularia Species 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 17
- 230000006907 apoptotic process Effects 0.000 abstract description 13
- 206010025323 Lymphomas Diseases 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 206010059866 Drug resistance Diseases 0.000 abstract description 2
- 230000035755 proliferation Effects 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 241000246044 Sophora flavescens Species 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 238000012856 packing Methods 0.000 description 10
- 230000001954 sterilising effect Effects 0.000 description 10
- 238000004659 sterilization and disinfection Methods 0.000 description 10
- 238000013461 design Methods 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 108090000672 Annexin A5 Proteins 0.000 description 3
- 102000004121 Annexin A5 Human genes 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000321096 Adenoides Species 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- -1 Suberyl Chemical group 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 210000002534 adenoid Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to an application of a Chinese and western combined medicine in preparing a medical composition for treating B cell lymphoma. The combined medicine consists of a western medicine and a traditional Chinese medicine, wherein the western medicine is SAHA; and the traditional Chinese medicine is prepared from the following raw material medicines in parts by weight: 5-15 parts of radix sophorae flavescentis, 5-10 parts of radix scrophulariae and 10-20 parts of cortex moutan. By adopting the combined medicine provided by the invention, the synergistic effect of the combined medicine is realized, the growth and proliferation of the B lymphoma cells can be synergistically suppressed, and the apoptosis of the B lymphoma cells is induced synergistically. The medicine combination can remarkably lower the cost and reduce the side effect while improving the curative effect. By utilizing the combined medicine provided by the invention, the shortcoming of drug resistance caused by using only one medicine in the prior art can be overcome.
Description
Technical field
The present invention relates to a kind of medicine, specifically, is the application of composition of medicine in pharmacy about the treatment B cell lymphoma.
Background technology
Lymphoma is to be primary in lymph node or adenoid malignant tumor.Clinical in Silent Neuritis, the carrying out property enlargement of lymph node is main manifestations greatly.Primary disease can betide any age, but the age of onset peak is at 31 ~ 40 years old, and wherein the non-Hodgkin lymphoma peak is slightly toward reach.Men and women's ratio is: 2 ~ 3:1.
Summary of the invention
The objective of the invention is for deficiency of the prior art, the application of a kind of Chinese and Western composition of medicine in the pharmaceutical composition of preparation treatment B cell lymphoma is provided.
For achieving the above object, the technical scheme that the present invention takes is: the application of a kind of Chinese and Western composition of medicine in the pharmaceutical composition of preparation treatment B cell lymphoma, described composition of medicine is comprised of Western medicine and Chinese medicine, described Western medicine is SAHA, and described Chinese medicine is to be made by the crude drug of following weight portion: Radix Sophorae Flavescentis 5-15 part, Radix Scrophulariae 5-10 part, Cortex Moutan 10-20 part.
Described Chinese medicine is to be made by the crude drug of following weight portion: Radix Sophorae Flavescentis 8-12 part, Radix Scrophulariae 6-9 part, Cortex Moutan 12-18 part.
Described Chinese medicine is to be made by the crude drug of following weight portion: 10 parts of Radix Sophorae Flavescentiss, 7 parts of Radix Scrophulariaes, 15 parts of Cortex Moutans.
Described SAHA and Chinese medicine ratio are 1-10mM:1-30mg/ml.
Described SAHA and Chinese medicine ratio are 2.5mM:20mg/ml.
The invention has the advantages that: the composition of medicine of the application of the invention, the synergism of performance composition of medicine can be worked in coordination with and be suppressed B lymphoma cell growing multiplication, co-induction B lymphoma cell apoptosis.Drug regimen can significantly reduce expense at present raising the same of curative effect, reduces side effect.Use composition of medicine of the present invention to overcome and be used alone the shortcoming that medicine causes drug resistance in prior art.
Description of drawings
Fig. 1 shows that flow cytometer detects the design sketch of SU-DHL-4 apoptosis matched group.
Fig. 2 shows the design sketch of alone Western medicine SU-DHL-4 apoptosis.
Fig. 3 shows the design sketch of alone Chinese medicine SU-DHL-4 apoptosis.
Fig. 4 shows the design sketch of combination with medication SU-DHL-4 apoptosis.
Fig. 5 shows that flow cytometer detects the design sketch of Daudi apoptosis matched group.
Fig. 6 shows the design sketch of alone Western medicine Daudi apoptosis.
Fig. 7 shows the design sketch of alone Chinese medicine Daudi apoptosis.
Fig. 8 shows the design sketch of combination with medication Daudi apoptosis.
The specific embodiment
The below elaborates to the specific embodiment provided by the invention.
Embodiment 1
Chinese medicine preparation (one)
Get sophora flavescens ait 100g, Radix Scrophulariae 70g, Cortex Moutan 150g and put and decoct in container, add the cold water soak 1h of 750g, boil 30 min, filter (2 times).Medicinal residues add 450g water to continue to decoct, and boil 20 min, filter (2 times).Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 5mg/ml in water-bath, the cooling sterilization medicine bottle of packing into is put 4 ℃ of refrigerators standby.
Embodiment 2
Chinese medicine preparation (two)
Get sophora flavescens ait 100g, Radix Scrophulariae 70g, Cortex Moutan 150g and put and decoct in container, add the cold water soak 1h of 750g, boil 30 min, filter (1 time).Medicinal residues add 450g water to continue to decoct, and boil 20 min, filter (2 times).Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 1mg/ml in water-bath, the cooling sterilization medicine bottle of packing into is put 4 ℃ of refrigerators standby.
Embodiment 3
Chinese medicine preparation (three)
Get sophora flavescens ait 100g, Radix Scrophulariae 70g, Cortex Moutan 150g and put and decoct in container, add the cold water soak 1h of 750g, boil 30 min, filter (2 times).Medicinal residues add 450g water to continue to decoct, and boil 20 min, filter (3 times).Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 10mg/ml in water-bath, the cooling sterilization medicine bottle of packing into is put 4 ℃ of refrigerators standby.
Embodiment 4
Chinese medicine preparation (four)
Get sophora flavescens ait 100g, Radix Scrophulariae 70g, Cortex Moutan 150g and put and decoct in container, add the cold water soak 1h of 750g, boil 30 min, filter (3 times).Medicinal residues add 450g water to continue to decoct, and boil 20 min, filter (4 times).Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 20mg/ml in water-bath, the cooling sterilization medicine bottle of packing into is put 4 ℃ of refrigerators standby.
Embodiment 5
Chinese medicine preparation (five)
Get sophora flavescens ait 100g, Radix Scrophulariae 70g, Cortex Moutan 150g and put and decoct in container, add the cold water soak 1h of 750g, boil 30 min, filter (2 times).Medicinal residues add 450g water to continue to decoct, and boil 20 min, filter (2 times).Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 30mg/ml in water-bath, the cooling sterilization medicine bottle of packing into is put 4 ℃ of refrigerators standby.
Embodiment 6
Chinese medicine preparation (six)
Get sophora flavescens ait 50g, Radix Scrophulariae 100g, Cortex Moutan 100g and put and decoct in container, add the cold water soak 1h of 750g, boil 30 min, filter (3 times).Medicinal residues add 450g water to continue to decoct, and boil 20 min, filter (4 times).Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 20mg/ml in water-bath, the cooling sterilization medicine bottle of packing into is put 4 ℃ of refrigerators standby.
Embodiment 7
Chinese medicine preparation (seven)
Get sophora flavescens ait 150g, Radix Scrophulariae 50g, Cortex Moutan 200g and put and decoct in container, add the cold water soak 1h of 750g, boil 30 min, filter (3 times).Medicinal residues add 450g water to continue to decoct, and boil 20 min, filter (4 times).Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 20mg/ml in water-bath, the cooling sterilization medicine bottle of packing into is put 4 ℃ of refrigerators standby.
Embodiment 8
Chinese medicine preparation (eight)
Get sophora flavescens ait 80g, Radix Scrophulariae 60g, Cortex Moutan 180g and put and decoct in container, add the cold water soak 1h of 750g, boil 30 min, filter (3 times).Medicinal residues add 450g water to continue to decoct, and boil 20 min, filter (4 times).Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 20mg/ml in water-bath, the cooling sterilization medicine bottle of packing into is put 4 ℃ of refrigerators standby.
Embodiment 9
Chinese medicine preparation (nine)
Get sophora flavescens ait 120g, Radix Scrophulariae 60g, Cortex Moutan 120g and put and decoct in container, add the cold water soak 1h of 750g, boil 30 min, filter (3 times).Medicinal residues add 450g water to continue to decoct, and boil 20 min, filter (4 times).Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 20mg/ml in water-bath, the cooling sterilization medicine bottle of packing into is put 4 ℃ of refrigerators standby.
Embodiment 10
Chinese medicine preparation (ten)
Get sophora flavescens ait 150g, Radix Scrophulariae 100g, Cortex Moutan 200g and put and decoct in container, add the cold water soak 1h of 750g, boil 30 min, filter (3 times).Medicinal residues add 450g water to continue to decoct, and boil 20 min, filter (4 times).Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 20mg/ml in water-bath, the cooling sterilization medicine bottle of packing into is put 4 ℃ of refrigerators standby.
Embodiment 11
Effect experiment
(1) reagent
Suberyl anilid hydroxamic acid (SAHA) is the hydroxamic acid histone deacetylases inhibitor, Radix Sophorae Flavescentis, Radix Scrophulariae, Cortex Moutan,
(2) cell culture
Following two kinds of cell strains have been used in this research: adopt the positive B lymphoma cell line SU-DHL-4 of CD20 and Daudi cell, cell is at 5%CO
2-95% air under the condition of saturated humidity and 37 ° of C, is incubated at (Gibco/BRL) in the RPMI-1640 culture fluid, and adds 10% hyclone.In each experiment, the cell inoculum density is 3 * 10
5/ ml.The survival rate of cell adopts platform to expect that orchid refuses to dye experiment and detect.Morphological observation adopts Wright Stain.
(3) MTT experiment
In 96 orifice plates, select 0,1,2.5,5,7.5 and 10mM with the SAHA final concentration, Chinese medicine (Radix Sophorae Flavescentis, Radix Scrophulariae and Cortex Moutan) group final concentration select 0,1,5,10,20 and 30mg/ml process cell.0 dosage group replaces with RPMI-1640.After 72 hours, add 0.1 mg MTT in every hole, after hatching 4 hours under 37 ℃, at spectrophotometer 570nm place's measurement specimen absorbance.
(4) flow cytometer detects annexin-V and mitochondrial transmembrane potentials:
Apoptosis is with ApoAlert Annexin V-FITC Apoptosis kit(BD) analyze.In detecting mitochondrial transmembrane potentials, after cell is washed with PBS, hatched 30 minutes with 10 mg/ml Rh123 under 37 ℃, and then dye with 50 mg/ml PI.Fluorescence intensity is measured with flow cytometer.
(5) immunoblotting assay:
With 200 ml Laemmli lysis buffers (0.5 M Tris-HCl, pH 6.8,2mM EDTA, 10% glycerol, 2% SDS and 5% b-mercaptoethanol) cracking 5x10
6Cell.Protein cleavage thing (20 mg) is used for 10% polyacrylamide gel electrophoresis, transfers on nitrocellulose filter.Nitrocellulose filter seals in being dissolved in 5% skim milk of TBS/0.05% Tween 20, afterwards with primary antibodie incubated at room 2 hours, with two anti-hatching 1 hour of horseradish peroxidase-labeled.Immune complex detects with the horseradish peroxidase chemiluminescence detection kit.
(6) nucleoprotein separates:
Every 1 * 10
7Cell and lysis buffer (10 mM HEPES, 10 mM KCl, 1.5 mM MgCl
2, 0.5 mM DTT, pH 7.9) wash after, be resuspended in Extraction buffer (20 mM HEPES, pH 7.9,420 mM NaCl, 0.5 mM DTT, 0.2 mM EDTA and 25% glycerol), hatched on ice 20 minutes.After centrifugal 10 minutes of 12000 * g, supernatant is nucleoprotein.
(7) statistical analysis:
Experimental result represents with meansigma methods and the standard deviation of three independent experiments, checks comparing difference with t.The P value thinks to have significant difference less than 0.05.All statistics adopt SAS8.2 software.
(8) result:
Adopt SU-DHL-4, the Daudi cell is cultivated, and reaches separately the impact of use in conjunction cell growth propagation by analysis and observation SAHA, Chinese medicine group.SAHA(2.5mM) Combined with Chinese Herbal medicine (20mg/ml) application can significantly suppress SU-DHL-4, the propagation of Daudi cell in 48 hours.
Detect alone and share the apoptosis (the two methods of dying of Annexin V and PI) of cell after medicine with flow cytometer.
SU-DHL-4(cell strain 1) through SAHA(2.5mM), Chinese medicine (20mg/ml) and SAHA(2.5mM) Combined with Chinese Herbal medicine (20mg/ml) is processed after 48 hours, Annexin V positive cell is respectively: matched group 3.4%(sees Fig. 1); SAHA group 26.3%(sees Fig. 2); Chinese medicine group 7.3%(sees Fig. 3); SAHA and Chinese medicine combination group 49.7%(see Fig. 4).
At Daudi(cell strain 2): matched group 3.0%(sees Fig. 5); SAHA group 24.2%(sees Fig. 6); Chinese medicine group 6.4%(sees Fig. 7); SAHA and Chinese medicine combination group 48.7%(see Fig. 8).
Simultaneously we use that Berenbaum sets up etc. the effect line-plot method use in conjunction of analyzing SAHA and Chinese medicine be work in coordination with, addition or antagonism.
Claims (5)
1. the application of Chinese and Western composition of medicine in the pharmaceutical composition of preparation treatment B cell lymphoma, described composition of medicine is comprised of Western medicine and Chinese medicine, it is characterized in that, described Western medicine is SAHA, and described Chinese medicine is to be made by the crude drug of following weight portion: Radix Sophorae Flavescentis 5-15 part, Radix Scrophulariae 5-10 part, Cortex Moutan 10-20 part.
2. application according to claim 1, is characterized in that, described Chinese medicine is to be made by the crude drug of following weight portion: Radix Sophorae Flavescentis 8-12 part, Radix Scrophulariae 6-9 part, Cortex Moutan 12-18 part.
3. application according to claim 1, is characterized in that, described Chinese medicine is to be made by the crude drug of following weight portion: 10 parts of Radix Sophorae Flavescentiss, 7 parts of Radix Scrophulariaes, 15 parts of Cortex Moutans.
4. application according to claim 1, is characterized in that, described SAHA and Chinese medicine ratio are 1-10 μ M:1-30 μ g/ml.
5. application according to claim 1, is characterized in that, described SAHA and Chinese medicine ratio are 2.5 μ M:20 μ g/ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013101242179A CN103169807A (en) | 2013-04-11 | 2013-04-11 | Application of Chinese and western combined medicine in pharmacy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013101242179A CN103169807A (en) | 2013-04-11 | 2013-04-11 | Application of Chinese and western combined medicine in pharmacy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103169807A true CN103169807A (en) | 2013-06-26 |
Family
ID=48630294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013101242179A Pending CN103169807A (en) | 2013-04-11 | 2013-04-11 | Application of Chinese and western combined medicine in pharmacy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103169807A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104857256A (en) * | 2015-04-27 | 2015-08-26 | 青岛大学附属医院 | Combination drug for curing B cell lymphoma |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1188011A (en) * | 1997-01-13 | 1998-07-22 | 任玉让 | Chinese herbal medicine composition for curing malignant lymphoma |
| CN1504218A (en) * | 2002-11-29 | 2004-06-16 | 李彦群 | Medicine composition for tumour and its preparation method |
| CN1824307A (en) * | 2005-12-28 | 2006-08-30 | 上海交通大学医学院附属瑞金医院 | A kind of pharmaceutical composition for treating B-cell lymphoma |
| CN1876060A (en) * | 2005-08-15 | 2006-12-13 | 曹国荣 | Three dimensional therapy for treating cancer and pharmaceutical composition thereof |
| CN101926882A (en) * | 2010-08-25 | 2010-12-29 | 曹国荣 | Medicinal composition for treating cancer and preparation methods thereof |
| CN102188415A (en) * | 2003-08-26 | 2011-09-21 | 默克Hdac研究有限责任公司 | Method of treating cancer with HDAC inhibitors |
| CN102579999A (en) * | 2012-03-21 | 2012-07-18 | 山东省千佛山医院 | Medicine for treating carcinous fever and preparation method thereof |
| CN102600394A (en) * | 2012-03-05 | 2012-07-25 | 王洪丽 | Traditional Chinese medicine for treating radiodermatitis |
-
2013
- 2013-04-11 CN CN2013101242179A patent/CN103169807A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1188011A (en) * | 1997-01-13 | 1998-07-22 | 任玉让 | Chinese herbal medicine composition for curing malignant lymphoma |
| CN1504218A (en) * | 2002-11-29 | 2004-06-16 | 李彦群 | Medicine composition for tumour and its preparation method |
| CN102188415A (en) * | 2003-08-26 | 2011-09-21 | 默克Hdac研究有限责任公司 | Method of treating cancer with HDAC inhibitors |
| CN1876060A (en) * | 2005-08-15 | 2006-12-13 | 曹国荣 | Three dimensional therapy for treating cancer and pharmaceutical composition thereof |
| CN1824307A (en) * | 2005-12-28 | 2006-08-30 | 上海交通大学医学院附属瑞金医院 | A kind of pharmaceutical composition for treating B-cell lymphoma |
| CN101926882A (en) * | 2010-08-25 | 2010-12-29 | 曹国荣 | Medicinal composition for treating cancer and preparation methods thereof |
| CN102600394A (en) * | 2012-03-05 | 2012-07-25 | 王洪丽 | Traditional Chinese medicine for treating radiodermatitis |
| CN102579999A (en) * | 2012-03-21 | 2012-07-18 | 山东省千佛山医院 | Medicine for treating carcinous fever and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 刘艳艳等: "《第十次全国淋巴瘤学术会议论文汇编》", 31 December 2007 * |
| 崔虎军: "恶性淋巴瘤中西医结合临床治疗进展", 《浙江中医药大学学报》 * |
| 王燕等: "复方苦参注射液联合CTOP方案治疗弥漫大B细胞淋巴瘤50例", 《中国现代药物应用》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104857256A (en) * | 2015-04-27 | 2015-08-26 | 青岛大学附属医院 | Combination drug for curing B cell lymphoma |
| CN104857256B (en) * | 2015-04-27 | 2018-04-10 | 青岛大学附属医院 | A kind of composition of medicine for treating B cell lymphoma |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Han | Rutin has therapeutic effect on septic arthritis caused by Candida albicans | |
| da Silva et al. | Berberine antifungal activity in fluconazole-resistant pathogenic yeasts: action mechanism evaluated by flow cytometry and biofilm growth inhibition in Candida spp | |
| Da-Yong et al. | Herbal medicine in new era | |
| Menke et al. | Taraxacum officinale extract shows antitumor effects on pediatric cancer cells and enhance mistletoe therapy | |
| Caggiano et al. | Candida bloodstream infections in Italy: changing epidemiology during 16 years of surveillance | |
| Uesato et al. | Synergistic antitumor effect of a combination of paclitaxel and carboplatin with nobiletin from Citrus depressa on non-small-cell lung cancer cell lines | |
| Kim et al. | Ethanol extract of Ocimum sanctum exerts anti-metastatic activity through inactivation of matrix metalloproteinase-9 and enhancement of anti-oxidant enzymes | |
| Ahmed et al. | Bioactivity and cytotoxic effect of cyanobacterial toxin against hepatocellular carcinoma | |
| Zhu et al. | It is not just folklore: the aqueous extract of mung bean coat is protective against sepsis | |
| Cao et al. | Physalin B induces G2/M cell cycle arrest and apoptosis in A549 human non-small-cell lung cancer cells by altering mitochondrial function | |
| CN107595834A (en) | Quercetin and curcumin drug combination are preparing the application in treating prostate cancer product | |
| CN103169807A (en) | Application of Chinese and western combined medicine in pharmacy | |
| CN103156951A (en) | Combined medicament for treating B cell lymphoma | |
| CN103223023A (en) | T-cell lymphoma treatment combination drug | |
| CN103191405A (en) | Combination medicine containing bortezomib | |
| CN103191406A (en) | Application of combination medicine to lymphoma | |
| Osonwa et al. | Antiplasmodial and Biochemical Effects of Combination of Ethanolic Leave-extracts of Azadirachta indica and Ocimum gratissimum on Plasmodium berghei-infected Mice | |
| Chang et al. | Consolidation chwemotherapy after concurrent chemoradiotherapy vs. chemoradiotherapy alone for locally advanced unresectable stage III non-small-cell lung cancer: A meta-analysis | |
| CN103191425A (en) | Combination medicine containing rituximab and lightyellow sophora root | |
| Mehta et al. | Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapy | |
| CN103191209A (en) | Application of combination medicine to leukemia | |
| CN103191426A (en) | New application of rituximab and traditional Chinese medicine | |
| Ha et al. | Genotoxicity assessment of a herbal formula, Ojeok-san | |
| Vaezi et al. | In vitro activity of juglone (5-hydroxy-1, 4-naphthoquinone) against both fluconazole-resistant and susceptible Candida isolates | |
| Al-Zubairi | In vitro genotoxic effects of zerumbone and cisplatin combination in CHO cell lines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130626 |